Posts Tagged ‘france’

Biotech Jobs in France Given Boost

Thursday, April 15th, 2010

Biotechnology Jobs, Biotechnology Recruitment, CK Science, UKThe global pharmaceutical company, Sanofi-Aventis, is set to invest over 150 million Euros to improve its biotechnology manufacturing facilities in France. The move will give a good boost to biotechnology jobs in France.

Biotech jobs will be created through a shift in chemical activities in France towards biotechnology and vaccine production by 2014.

The pharmaceutical company plans to create a new biosynthetic process in the plants of Saint-Aubin-Les-Elbeuf, in North Western France, and Vertolaye, in central France, in order to improve its global competitiveness on corticosteroid output. As a result there will be many biotechnology jobs created.

This biotechnology job creation will be off-set by plans to close the companies Romainville plant, in North Western France, by the end of 2013. Sanofi have said that this closure will be accompanied by a ‘job stimulus plan’.

Philippe Luscan, Head of Industrial Affairs stated, “There is a balance between a reduction in chemical jobs and a rise in biotechnology jobs, so the number of jobs will be steady overall.”

The project will also bring about measures to improve career progression by implementing biotechnology training programmes for 700 employees. This will be facilitated through a partnership with French Universities.

Looking for a new job in biotechnology? Click here to search for our latest biotechnology job vacancies.

CK Science - Science Jobs, Scientific Recruitment, UKTwitter - CK Science, Scientific Recruitment, Scientific Jobs, UKFacebook - CK Science, Science Jobs, Scientific Recruitment, UKLinkedin - CK Science, Science Jobs, Scientific Recruitment, UKYoutube - CK Science, Scientific Jobs, Scientific Recruitment, UK

Teva Buys Ratiopharm in Generic Drugs Deal

Monday, March 22nd, 2010

Teva and Ratiopharm DealAs reported by the  BBC News the Israeli drugs giant, Teva has bought Germany’s second largest generics drug firm Ratiopharm for £3.2bn. Teva beat rival bids from U.S. pharmaceutical powerhouse Pfizer and Iceland’s Actavis.

Teva is already the world’s largest generic drug maker, and as a result of this deal is now number one in Europe, beating Novartis’ generics unit. The deal is also set to increase their presence in Spain, Italy and France.

Teva’s Chief Executive Shlomo Yanai stated, “This is an important acquisition for Teva, This transaction is perfectly aligned with our long-term strategy in which Europe is an important pillar and growth-driver.”

Generics are based around drug patents that have expired, allowing companies to both manufacture and sell them and is therefore seen as a high growth market.

CKS01twittercksciencelinkedinfacebookckclinical youtube

Search for a job

Advanced search

20 years Download the CK Science iPhone App

Subscribe to our newsletter

Preview
Powered by FeedBlitz